MAPK3 and cancer: The ability of cancer cells to resist apoptosis during long-term CTS treatment (Figures 3 & 4A) led us to consider whether ERK1/2 signaling kinases are activated during long-term CTS treatment, which might enable proliferation and cell survival mechanisms.